CoChat
Sign Up
Cited by 11Thyroid Cancer Diagnosis and TreatmentTGF-β signaling in diseasesCancer Cells and Metastasis

Snail-1 Overexpression Correlates with Metastatic Phenotype in BRAFV600E Positive Papillary Thyroid Carcinoma

Open access
Wieczorek-Szukala, Katarzyna, Kopczynski, Janusz, Kowalska, Aldona, Lewinski, Andrzej·2020·Journal of Clinical Medicine
DOI 10.3390/jcm9092701PMC PMC7565998
Open this paper in CoChat — free accountOpen PDF

Abstract

The ability of cancer to metastasize is regulated by various signaling pathways, including transforming growth factor β (TGFβ), also implicated in the upregulation of Snail-1 transcription factor in malignant neoplasms. B-type Raf kinase gene (BRAF)V600E, the most common driving mutation in papillary thyroid carcinoma (PTC), induces epithelial to mesenchymal transition (EMT) in thyroid cancer cells through changes in the Snail-1 level, increasing cell migration and invasion. However, little is known about the mechanism of Snail-1 and BRAFV600E relations in humans. Our study included 61 PTC patients with evaluated BRAFV600E mutation status. A total of 18 of those patients had lymph node metastases—of whom 10 were BRAFV600E positive, and 8 negative. Our findings indicate that the expression of Snail-1, but not TGFβ1, correlates with the metastatic phenotype in PTC. This is the first piece of evidence that the upregulation of Snail-1 corresponds with the presence of BRAFV600E mutation and increased expression of Snail-1 in metastatic PTC samples is dependent on BRAFV600E mutation status.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jcm9092701

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Upregulation of pioneer developmental organizers such as SOX2, KLF4, β-catenin, SNAIL-1, c-MYC, TBX3, and BCL6 is reported downstream of BRAF/MAPK-driven tumor.

    “Even upregulation of pioneer developmental organizers, such as SOX2, KLF4, β-catenin, SNAIL-1, c-MYC, TBX3, BCL6, et al., are reported downstream of BRAF/MAPK-driven tumor, the pathways causing lineage reprogramming are not clear12,15,30–36.”

    From Proteostatic reactivation of the developmental transcription factor TBX3 drives BRAF/MAPK-mediated tumorigenesis (2024) · cites this paper as [36]

    The Discussion (page unavailable) reports higher Snail-1 expression specifically in metastatic papillary thyroid carcinomas with a BRAFV600E mutation, and suggests that the mutation may facilitate its overexpression. The paper does not report BRAF/MAPK-driven upregulation of SOX2, KLF4, β-catenin, c-MYC, TBX3, or BCL6, or establish the broader downstream relationship claimed. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 34

  1. [1]Agrawal N. Akbani R. Aksoy B.A. Ally A. Arachchi H. Asa S.L. Auman J.T. Balasundaram M. Balu S. Baylin S.B. Integrated Genomic Characterization of Papillary Thyroid Carcinoma Cell 2014 159 676 690 10.1016/j.cell.2014.09.050 25417114 PMC4243044 · DOI
  2. [3]Coghlin C. Murray G. Current and emerging concepts in tumour metastasis J. Pathol. 2010 222 1 15 10.1002/path.2727 20681009 · DOI
  3. [4]Tania M. Khan M.A. Fu J. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer Tumor Biol. 2014 35 7335 7342 10.1007/s13277-014-2163-y 24880591 · DOI
  4. [5]Shakib H. Rajabi S. Dehghan M. Mashayekhi F.J. Safari-Alighiarloo N. Hedayati M. Epithelial-to-mesenchymal transition in thyroid cancer: A comprehensive review Endocrine 2019 66 435 455 10.1007/s12020-019-02030-8 31378850 · DOI
  5. [6]Liu Z. Kakudo K. Bai Y. Li Y. Ozaki T. Miyauchi A. Taniguchi E. Mori I. Loss of cellular polarity/cohesiveness in the invasive front of papillary thyroid carcinoma, a novel predictor for lymph node metastasis; possible morphological indicator of epithelial mesenchymal transition J. Clin. Pathol. 2011 64 325 329 10.1136/jcp.2010.083956 21296795 · DOI
  6. [7]Pisarev M.A. Thomasz L. Juvenal G. Role of transforming growth factor beta in the regulation of thyroid function and growth Thyroid 2009 19 881 892 10.1089/thy.2007.0303 19645615 · DOI
  7. [8]Wang N. Jiang R. Yang J.Y. Tang C. Yang L. Xu M. Jiang Q.F. Liu Z.M. Expression of TGF-β1, SNAI1 and MMP-9 is associated with lymph node metastasis in papillary thyroid carcinoma J. Mol. Hist. 2014 45 391 399 10.1007/s10735-013-9557-9 24276590 · DOI
  8. [9]Kaufhold S. Bonavida B. Central role of Snail1 in the regulation of EMT and resistance in cancer: A target for therapeutic intervention J. Exp. Clin. Cancer Res. 2014 33 62 10.1186/s13046-014-0062-0 25084828 PMC4237825 · DOI
  9. [10]Skovierova H. Okajcekova T. Strnadel J. Vidomanova E. Halasova E. Molecular regulation of epithelial-to-mesenchymal transition in tumorigenesis Int. J. Mol. Med. 2018 41 1187 1200 29286071 PMC5819928
  10. [11]Murray S.A. Gridley T. Snail1 gene function during early embryo patterning in mice Cell Cycle 2006 5 2566 2570 10.4161/cc.5.22.3502 17106264 · DOI
  11. [12]Wawro M.E. Sobierajska K. Ciszewski W.M. Wagner W. Frontczak M. Wieczorek K. Niewiarowska J. Tubulin beta 3 and 4 are involved in the generation of early fibrotic stages Cell Signal. 2017 38 26 38 10.1016/j.cellsig.2017.06.014 28648944 · DOI
  12. [13]Ota I. Masui T. Kurihara M. Yook J. Mikami S. Kimura T. Shimada K. Konishi N. Yane K. Yamanaka T. Snail-induced EMT promotes cancer stem cell-like properties in head and neck cancer cells Oncol. Rep. 2016 35 261 266 10.3892/or.2015.4348 26498709 · DOI
  13. [14]Brzozowa M. Michalski M. Wyrobiec G. Piecuch A. Dittfeld A. Harabin-Słowińska M. Boroń D. Wojnicz R. The role of Snail1 transcription factor in colorectal cancer progression and metastasis Contemp. Oncol. 2015 19 265 270 10.5114/wo.2014.42173 26557772 PMC4631295 · DOI
  14. [15]Shin N.R. Jeong E.H. Choi C. Moon H.J. Kwon C. Chu I.S. Kim G.H. Jeon T.Y. Kim D. Lee J. Overexpression of Snail is associated with lymph node metastasis and poor prognosis in patients with gastric cancer BMC Cancer 2012 12 521 10.1186/1471-2407-12-521 23151184 PMC3552976 · DOI
  15. [16]Christofori G. New signals from the invasive front Nature 2006 441 444 450 10.1038/nature04872 16724056 · DOI
  16. [17]Wieczorek K. Wiktorska M. Sacewicz-Hofman I. Boncela J. Lewiński A. Kowalska M.A. Niewiarowska J. Filamin A upregulation correlates with Snail-induced epithelial to mesenchymal transition (EMT) and cell adhesion but its inhibition increases the migration of colon adenocarcinoma HT29 cells Exp. Cell. Res. 2017 359 163 170 10.1016/j.yexcr.2017.07.035 28778796 · DOI
  17. [18]Sobierajska K. Wieczorek K. Ciszewski W.M. Sacewicz-Hofman I. Wawro M.E. Wiktorska M. Boncela J. Papiewska-Pajak I. Kwasniak P. Wyroba E. β-III tubulin modulates the behavior of Snail overexpressed during the epithelial-to-mesenchymal transition in colon cancer cells J. Biochim. Biophys. Acta 2016 1863 2221 2233 10.1016/j.bbamcr.2016.05.008 27188792 · DOI
  18. [19]Yang X. Shi R. Zhang J. Co-expression and clinical utility of Snail and N-cadherin in papillary thyroid carcinoma Tumor Biol. 2016 37 413 417 10.1007/s13277-015-3820-5 26219900 · DOI
  19. [20]Lewiński A. Adamczewski Z. Zygmunt A. Markuszewski L. Karbownik-Lewińska M. Stasiak M. Correlations between molecular landscape and Sonographic image of different variants of papillary thyroid carcinoma J. Clin. Med. 2019 8 1916 10.3390/jcm8111916 PMC6912205 31717363 · DOI
  20. [21]Tufano R.P. Teixeira G.V. Bishop J. Carson K.A. Xing M. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: A systematic review and meta-analysis Medicine 2012 91 274 286 10.1097/MD.0b013e31826a9c71 22932786 · DOI
  21. [22]Knauf J.A. Sartor M.A. Medvedovic M. Lundsmith E. Ryder M. Salzano M. Nikiforov Y.E. Giordano T.J. Ghossein R.A. Fagin J.A. Progression of BRAF-induced thyroid cancer is associated with epithelial–mesenchymal transition requiring concomitant MAP kinase and TGF beta signaling Oncogene 2011 30 3153 3162 10.1038/onc.2011.44 21383698 PMC3136543 · DOI
  22. [23]Tang K. Lee C. BRAF mutation in papillary thyroid carcinoma: Pathogenic role and clinical implications J. Chin. Med. Assoc. 2010 73 113 128 10.1016/S1726-4901(10)70025-3 20230995 · DOI
  23. [24]Li C. Han P. Lee K.C. Lee L. Fox A.C. Beninato T. Thiess M. Dy B.M. Sebo T. Thompson G.B. Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers J. Clin. Endocrinol. Metab. 2013 9 3702 3712 10.1210/jc.2013-1584 23969188 · DOI
  24. [25]Baquero P. Sánchez-Hernández I. Jiménez-Mora E. Orgaz J.L. Jiménez B. Chiloeches A. V600E BRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadherin expression through a Snail-dependent mechanism Cancer Lett. 2013 335 232 241 10.1016/j.canlet.2013.02.033 23435375 · DOI
  25. [26]Massoumi R. Kuphal S. Hellerbrand C. Haas B. Wild P. Spruss T. Pfeifer A. Fässler R. Bosserhoff A.K. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma J. Exp. Med. 2009 206 221 232 10.1084/jem.20082044 19124656 PMC2626666 · DOI
  26. [27]Baquero P. Jimenez-Mora E. Santos A. Lasa M. Chiloeches A. TGFβ induces epithelial-mesenchymal transition of thyroid cancer cells by both the BRAF/MEK/ERK and Src/FAK pathways Mol. Carcinog. 2016 55 1639 1654 10.1002/mc.22415 26392228 · DOI
  27. [28]Walczyk A. Kowalska A. Kowalik A. Sygut J. Wypiórkiewicz E. Chodurska R. Pięciak L. Góźdź S. The BRAF (V600E) mutation in papillary thyroid microcarcinoma: Does the mutation have an impact on clinical outcome? Clin. Endocrinol. 2014 80 899 904 10.1111/cen.12386 24354346 · DOI
  28. [29]Kowalik A. Kowalska A. Walczyk A. Chodurska R. Kopczyński J. Chrapek M. Wypiórkiewicz E. Chłopek M. Pięciak L. Gąsior-Perczak D. Evaluation of molecular diagnostic approaches for the detection of BRAF p.V600E mutations in papillary thyroid cancer: Clinical implications PLoS ONE 2017 12 e0179691 10.1371/journal.pone.0179691 28636673 PMC5479585 · DOI
  29. [30]Brace M.D. Wang J. Petten M. Bullock M.J. Makki F. Trites J. Taylor S.M. Hart R.D. Differential expression of transforming growth factor-beta in benign vs. papillary thyroid cancer nodules; A potential diagnostic tool? J. Otolaryngol.-Head Neck Surg. 2014 43 22 10.1186/s40463-014-0022-x 25927212 PMC4115165 · DOI
  30. [31]Pang M.F. Georgoudaki A.M. Lambut L. Johansson J. Tabor V. Hagikura K. Jin Y. Jansson M. Alexander J.S. Nelson C.M. TGF-β1-induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR7/CCL21-mediated chemotaxis Oncogene 2016 35 748 760 10.1038/onc.2015.133 25961925 PMC4753256 · DOI
  31. [32]Wang S. Liu J. Wang C. Lin B. Hao Y. Wang Y. Gao S. Qi Y. Zhang Y. Iwamori M. Expression and correlation of Lewis y antigen and TGF-β1 in ovarian epithelial carcinoma Oncol. Rep. 2012 27 1065 1071 10.3892/or.2011.1575 22138668 PMC3583523 · DOI
  32. [34]Dhasarathy A. Phadke D. Mav D. Shah R.R. Wade P.A. The transcription factors Snail and Slug activate the transforming growth factor-beta signaling pathway in breast cancer PLoS ONE 2011 6 e26514 10.1371/journal.pone.0026514 22028892 PMC3197668 · DOI
  33. [35]Mitchell B. Leone D.A. Feller J.K. Yang S. Mahalingam M. BRAF and epithelial-mesenchymal transition in primary cutaneous melanoma: A role for Snail and E-cadherin? Hum. Pathol. 2016 52 19 27 10.1016/j.humpath.2015.12.030 26980024 · DOI
  34. [36]McCubrey J.A. Steelman L.S. Bertrand F.E. Davis N.M. Sokolosky M. Abrams S.L. Montalto G. D’Assoro A.B. Libra M. Nicoletti F. GSK-3 as potential target for therapeutic intervention in cancer Oncotarget 2014 5 2881 2911 10.18632/oncotarget.2037 24931005 PMC4102778 · DOI

Cited by

Sorted by citations

Authors
Wieczorek-Szukala, K., Kopczynski, J., Kowalska, A., & Lewinski, A.
Affiliations
  • Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, 93-338 Lodz, Poland
  • Department of Pathology, Holy Cross Cancer Center, 25-734 Kielce, Poland
  • Jan Kochanowski University (PL)
ORCID
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2020-08-21
Volume
9
Issue
9
Pages
2701
ISSN
2077-0383 (ISSN-L)
DOI
10.3390/jcm9092701
PMC
PMC7565998
OpenAlex
W3063492462
Cited by
11
References
1
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 3
FWCI
1.32
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
SNAI1, BRAF V600E mutation, papillary thyroid carcinoma, lymph node metastasis, epithelial-mesenchymal transition, TGF-β1, metastatic phenotype, gene overexpression, cell migration and invasion

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review